Replies to post #559493 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Thanks for the reply. Your statement is verifiably false.

1. PFS data were contaminated data and therefore invalid. PFS is a surrogate predictor of OS. The trial design was adapted to wait for OS data.

2. OS was always one of the endpoints.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847

[dennisdave]

The -L P3 just saw that endpoint failed and then changed them.

Even if thats true, which its not the trial was blinded when endpoints were changed, then still thats well within FDA/EMA regulations. Anything that has to do with regulation and law isnt really your strong suit is it?